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Background: The inhibition of dipeptidyl peptidase (DPP) IV shows protective effects on tissue injury of the heart, lung,
and kidney. Forkhead box O (FoxO) transcriptional factors regulate cellular differentiation, growth, survival, the cell cycle,
metabolism, and oxidative stress. The aims of this study were to investigate whether the DPP IV inhibitor sitagliptin
could attenuate kidney injury and to evaluate the status of FoxO3a signaling in the rat remnant kidney model.
Methods: Rats were received two-step surgery of 5/6 renal mass reduction and fed on an oral dose of 200 mg/kg/day
sitagliptin for 8 weeks. Before and after the administration of sitagliptin, physiologic parameters were measured. After
8 weeks of treatment, the kidneys were harvested.
Results: The sitagliptin treatment attenuated renal dysfunction. A histological evaluation revealed that
glomerulosclerosis and tubulointerstitial injury were significantly decreased by sitagliptin. Sitagliptin decreased DPP IV
activity and increased the renal expression of glucagon-like peptide-1 receptor (GLP-1R). The subtotal nephrectomy led
to the activation of phosphatidylinositol 3-kinase (PI3K)-Akt and FoxO3a phosphorylation, whereas sitagliptin treatment
reversed these changes, resulting in PI3K-Akt pathway inactivation and FoxO3a dephosphorylation. The renal expression
of catalase was increased and the phosphorylation of c-Jun N-terminal kinase (JNK) was decreased by sitagliptin.
Sitagliptin treatment reduced apoptosis by decreasing cleaved caspase-3 and −9 and Bax levels and decreased
macrophage infiltration.
Conclusions: In rat remnant kidneys, DPP IV inhibitor attenuated renal dysfunction and structural damage. A reduction
of apoptosis, inflammation and an increase of antioxidant could be suggested as a renoprotective mechanism together
with the activation of FoxO3a signaling. Therefore, DPP IV inhibitors might provide a promising approach for treating
CKD, but their application in clinical practice remains to be investigated.
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Glucagon-like peptide-1 (GLP-1) is a gut incretin hormone,
whose mimetics have been used as a therapeutic agent for
type 2 diabetes. It stimulates pancreatic beta cell prolifera-
tion and insulin secretion in a glucose-dependent manner
[1]. However, this peptide is almost immediately degraded
by dipeptidyl peptidase (DPP) IV in the circulation. DPP IV* Correspondence: kyna@snubh.org
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reproduction in any medium, provided the orhas a wide variety of substrates that have important roles in
cell migration and differentiation, glucose regulation,
metabolism, and inflammation [2]. Sitagliptin, a highly
selective DPP IV inhibitor, is currently used in the
treatment of type 2 diabetes patients to improve
glucose tolerance by increasing the half-life of GLP-1 and
glucose-dependent insulinotropic peptide (GIP) [3].
The GLP-1 receptor (GLP-1R) agonist exendin-4 has
been reported to ameliorate diabetic nephropathy in
animals [4,5]. Recently, studies have shown that DPP IV
inhibitors attenuate kidney injury in diabetic animal models
[6,7]. In addition to diabetic nephropathy, DPP IV inhi-
bition protected the kidney against ischemia-reperfusion
injury (IRI) [8]. Tissue protective effects of GLP-1 activation. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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organs, including IRI of the lung during transplantation
[9-11] and the outcome of myocardial infarction [12,13].
Most cases of chronic kidney disease (CKD) inevitably
progress to end-stage renal disease, which has a high
associated morbidity and mortality. Although the initiating
insult of CKD is variable, the progression of the disease
seems to be common to all kidney diseases that involve a
vicious cycle of nephron destruction, glomerulosclerosis
and tubulointerstitial fibrosis [14]. However, few pharmaco-
logic treatments have been shown to attenuate the progres-
sion of CKD. The remnant kidney is a disease model that
mimics the progression of CKD in humans. In this model,
there is early glomerulosclerosis by week 4, with segmental
sclerosis with tubulointerstitial fibrosis by week 8. Animals
die of uremia starting at week 12 to week 16 [15].
Therefore, 8 weeks after subtotal nephrectomy must
be a proper time to observe renal pathology in this model.
Forkhead box O (FoxO) transcriptional factors regu-
late various downstream target genes, including those
involved in cellular differentiation, growth, survival, the
cell cycle, glucose and lipid metabolism, stress, and the
detoxification of reactive oxygen species (ROS) [16]. The
phosphatidylinositol 3-kinase (PI3K) and serine–threonine
kinase Akt/PKB (Akt) pathway regulates FoxO through
phosphorylation. The Akt-mediated phosphorylation of
FoxO inhibits the activity of FoxO by promoting its inter-
action with 14-3-3 proteins and its nuclear exportation,
and also by inducing its degradation by the proteasome
[17]. In the kidney, the FoxO3 transcript is the most abun-
dant among four subfamily members of FoxO proteins
[18]. However, there is no study on the status of FoxOs in
the remnant kidney model.
Based on the previous reports of tissue protective
effects, we hypothesize that DPP IV inhibition could
have a positive effect on this animal model of CKD. Due to
the diverse regulatory functions of FoxO, our hypothesis is
that its signaling might also be modulated by DPP IV
inhibition in this model. Therefore, it would be interesting
to investigate FoxO signaling in the kidneys. The present
study aimed to evaluate whether sitagliptin could attenuate
kidney injury in a rat remnant kidney model. Moreover, we
investigated the status of FoxO3a signaling after sitagliptin
treatment in this model. To do this, we made CKD animal
model by two-step surgery of 5/6 renal mass reduction,




All animal procedures were approved by the Institutional
Animal Care and Use Committee of the Medical Science
Research Institute, Seoul National University Bundang
Hospital (BA 1112-095/080-01). Male Sprague–Dawleyrats (Orient Bio Inc., Seongnam, South Korea) weighing
approximately 200 g were used. The rats (n = 21) were
randomly assigned to three groups: sham-operation
(sham), subtotal nephrectomy (Nx), and subtotal nephrec-
tomy + sitagliptin treatment (Nx+STG) groups. After a
right subcostal incision, the right kidney was exposed and
separated from the adrenal gland under anesthesia with
enflurane (Choongwae Pharma Corp., Seoul, South
Korea). The lower and upper thirds of the right kidney
were resected. After 1 week, the left kidney was removed.
The rats of the sham group underwent the same incision
and manipulation of the left and the right kidneys without
tissue destruction. One week after the second surgical
intervention, the rats in the Nx+STG group were fed a
gelled diet containing 200 mg/kg/day of sitagliptin (MSD
Korea, Seoul, South Korea), and the rats in the sham and
Nx group were fed same gelled diet without sitagliptin.
After 8 weeks of treatment, the animals were anesthetized
with enflurane, blood samples were obtained, and the
kidneys were collected. One portion of the right kidney
was fixed in 10% phosphate-buffered formalin for morpho-
logic and immunohistochemical analyses. The remainder of
the right kidney was snap-frozen in liquid nitrogen and
stored at −80°C for protein extraction.
Physiologic measurements
Before and after the administration of a gelled diet with
or without sitagliptin, the rats were weighed and placed
in metabolic cages, and their urine was collected for 24 h.
The urine volume was measured. Serum samples were
taken from the tail vein. The blood glucose levels were
measured by an Accu-check meter (Roche diagnostics, St
Louis, MO, USA). BUN and creatinine levels in the serum
and urine were measured using an automatic analyzer
(ADVIA 1650, Siemens, Berlin, Germany). Creatinine
clearance was calculated and adjusted for body weight.
Determination of DPP IV enzymatic activity
DPP IV enzymatic activity was assayed in serum using DPP
IV Activity Assay Kit (Biovision, Milpitas, CA, USA). A
50 μl volume of serum was diluted with 48 μl of DPP IV
assay buffer and mixed with 2 μl substrate Gly-Pro-7-
Amino-4-Methylcoumarin (AMC) and then incubated at
37°C for 30 min. The release of AMC from the substrate
was measured with a fluorescence spectrophotometer at
360 nm of excitation and 460 nm of emission.
Renal histologic and immunohistochemical analyses
Tissue for light microscopy and immunoperoxidase
staining was fixed in formalin and embedded in paraf-
fin. Three-micrometer sections were stained with
hematoxylin and eosin (H&E). Apoptosis was detected
with the enzymatic labeling of DNA strand breaks
using terminal deoxynucleotidyl transferase-mediated
Table 1 Physiologic parameters of experimental animals
Sham (n=6) Nx (n=8) Nx+STG (n=7)
Body weight (g)
Initial 205 ± 8 204 ± 9 199 ± 10
Final 563 ± 34 493 ± 29* 475 ± 31*
Blood glucose (mg/dl)
Initial 111 ± 11 100 ± 10 111 ± 6
Final 180 ± 9 184 ± 21 172 ± 21
BUN (mg/dl)
Initial 8.27 ± 2.48 8.63 ± 1.56 9.94 ± 3.41
Final 12.17 ± 2.50 28.19 ± 3.56* 25.04 ± 7.12*
Cr (mg/dl)
Initial 0.39 ± 0.08 0.42 ± 0.06 0.39 ± 0.11
Final 0.52 ± 0.04 0.90 ± 0.09* 0.70 ± 0.19*#
ClCr (ml/min/100 g)
Initial 0.62 ± 0.25 0.52 ± 0.09 0.78 ± 0.33
Final 0.48 ± 0.05 0.31 ± 0.03* 0.43 ± 0.12#
The results are expressed as the mean ± s.d.
*Significantly different with respect to the sham-operated rats; #significantly
different with respect to the nephrectomized rats; *#P < 0.05.
Sham, sham operation; Nx, nephrectomy; Nx+STG, nephrectomy and
sitagliptin treatment.
Cr, creatinine; ClCr, creatinine clearance normalized to body weight.
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TUNEL staining was performed with a Cell Death
Detection kit (Roche, Mannheim, Germany). To reveal
the total nuclei, the same slides were stained with 4’,6’-
diamidino-2-phenyindole (DAPI) in phosphate-buffered
saline. Indirect immunoperoxidase staining with an anti-
ED-1 antibody (Serotec, Oxford, UK) was performed.
Quantification of morphologic data
All analyses were performed in a blinded manner.
Segmental and complete glomerular sclerosis was ana-
lyzed using a semiquantitative scoring system from 0
to 4 (0, no glomerulosclerosis; 1, <25% of glomerular
area affected; 2, 25–50% affected; 3, 50–75% affected;
and 4, 75–100% affected). At least 30 glomeruli were
evaluated under × 400 magnification, and the results
were averaged. The tubulointerstitial injury score was esti-
mated based on the number of tubule dilatations, the dis-
tortion of the tubular basement membranes, and atrophy
from 0 to 3 [0, none (<5%); 1, mild (5–25%); 2, moderate
(25–50%); and 3, severe (>50%)]. More than 10 consecutive
fields were examined under × 200 magnification, and the
results were averaged. TUNEL (+) apoptotic nuclei were
counted in more than 20 consecutive fields under × 200
magnification, and the results were averaged. The mean
numbers of infiltrating macrophages (ED-1 positive cells)
were calculated by averaging the total numbers of positive
cells in more than 20 sequentially-selected, 0.25-mm2 grids
at × 200 magnification.
Western blot analysis
Whole kidneys were homogenized in lysis buffer (250 mM
sucrose, 10 mM triethanolamine, 1 μg/ml leupeptin, and
0.1 mg/ml PMSF titrated to pH 7.6). The total protein con-
centration was measured using a bicinchoninic acid protein
assay reagent kit (Sigma, St. Louis, MO, USA). The samples
were run on SDS-polyacrylamide minigels (Bio-Rad Mini
Protean III). The proteins were transferred to nitrocellulose
membranes by electroelution. The following proteins
were detected using specific antibodies: GLP-1R
(Abcam, Cambridge, UK), β-actin (Santa Cruz Biotech,
Santa Cruz, CA, USA), PI3K (BD Bioscience, Franklin
Lakes, NJ, USA), total Akt, phospho-Ser473 Akt, total
FoxO3a, phospho-Ser253 FoxO3a, total c-Jun N-terminal
kinase (JNK), phospho-Thr183/Tyr185 JNK, caspase-3
(all from Cell Signaling Technology, Danvers, MA, USA),
caspase-9 (BD Bioscience), Bax (Santa Cruz Biotech),
and catalase (Abcam). After incubation with peroxidase-
conjugated secondary antibodies (Pierce no. 31458,
Rockford, IL, USA), bands were visualized using an
enhanced chemiluminescence substrate (ECLTM RPN
2106; Amersham Pharmacia Biotech, Buckinghamshire,
UK) before exposure to X-ray film (Hyperfilm; Amersham
Pharmacia Biotech, Buckinghamshire, UK). The banddensities were quantified by densitometry (GS-700
Imaging Densitometry, Bio-Rad, Hercules, CA, USA).
Statistical analysis
All of the data are presented as the means ± S.D. The statis-
tical analyses were performed using SPSS (version 15.0. for
Windows; SPSS Inc., Chicago, IL, USA). Difference among
three groups were tested with one-way analysis of variance
(ANOVA), followed by Turkey’s multiple comparison
post-test. Statistical significance was indicated by P < 0.05.
Results
Table 1 shows the initial and final physiologic parameters
of the animals. At the end of the study, rats that received a
nephrectomy had a reduced body weight than the sham-
operated rats did. However, sitagliptin treatment did not
affect body weight or blood glucose levels in the animals.
The BUN level remained increased after nephrectomy but
was not significantly influenced by treatment with
sitagliptin. Serum creatinine levels were increased in the
nephrectomized rats, but they were significantly decreased
by sitagliptin treatment. Sitagliptin also significantly
improved creatinine clearance in nephrectomized
rats. Figure 1 shows a representative histological
image of the kidneys from each group of animals. In the
nephrectomized rats that received sitagliptin, the severity
of glomerulosclerosis was significantly reduced compared
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4
Figure 1 Effects of sitagliptin on renal histology. Representative images of H&E-stained renal tissues (A). Histological evaluation of glomerular
sclerosis (B) and tubulointerstitial injury (C). The extent of glomerular sclerosis and tubulointerstitial injury was evaluated and scored. The results
are expressed as the mean ± s.d. *Significantly different with respect to the sham-operated rats; #significantly different with respect to the
nephrectomized rats; *#P < 0.05. Sham, sham operation; Nx, nephrectomy; Nx+STG, nephrectomy and sitagliptin treatment. Magnification × 400
(upper panel) and x 200 (lower panel).
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degree of tubulointerstitial injury was also significantly
reduced by sitagliptin in the nephrectomized rats (score:
1.88 ± 0.64 vs. 2.71 ± 0.49, P < 0.05). From these results,
sitagliptin attenuated renal dysfunction and improved
histological damage induced by subtotal nephrectomy.
There was no difference in DPP IV activity in the
nephrectomized rats compared with the sham-operated
rats (Figure 2A). An almost complete DPP IV inhibition
was observed in serum of sitagliptin-treated rats with
less than 2% residual DPP IV activity. The expression of
GLP-1R in the kidney was reduced by half after 8 weeks of
subtotal nephrectomy (Figure 2B). However, treatment
with sitagliptin restored the expression of GLP-1R to the
level of sham-operated rats.
We determined the levels of PI3K and phospho-Akt in
the kidneys. The levels of PI3K and phospho-Akt in the
nephrectomized rats were significantly increased comparedto the sham-operated rats, whereas sitagliptin treatment of
nephrectomized rats significantly reduced both of these
levels (Figure 3). Because PI3K activation and Akt
phosphorylation serve as negative regulators of FoxO
transcription factors, we next examined the phospho-
rylation of FoxO3a. Western blotting showed that the
phospho-FoxO3a/total FoxO3a ratios were significantly
increased in the nephrectomized rats compared to the
sham-operated rats (Figure 4). However, the phospho-
FoxO3a/total FoxO3a ratios were significantly decreased by
sitagliptin treatment. Therefore, sitagliptin restored the
inactivation of FoxO3a induced by subtotal nephrectomy.
To investigate whether the status of FoxO3a phosphoryl-
ation affected downstream signaling activity, we examined
changes in the antioxidant protein catalase. As shown in
Figure 5A, the expression of catalase was significantly
increased by sitagliptin treatment. Because JNK is activated


































































Figure 2 Effects of sitagliptin on DPP IV activity and GLP-1 receptor expression. DPP IV enzymatic activity in serum of rats from each
group (A). Representative western blot and group data showing GLP-1 receptor protein abundance in the kidneys of rats from each group
(B). The intensity of the bands corresponding to the GLP-1 receptor was corrected by β-actin levels to obtain relative measures of GLP-1
receptor expression among all samples. The results are expressed as the mean ± s.d. *Significantly different with respect to the sham-operated
rats; #significantly different with respect to the nephrectomized rats; *#P < 0.05. Sham, sham operation; Nx, nephrectomy; Nx+STG, nephrectomy
and sitagliptin treatment.
Joo et al. BMC Nephrology 2013, 14:98 Page 5 of 11
http://www.biomedcentral.com/1471-2369/14/98However, there was no difference of the phospho-JNK/total
JNK ratios in the nephrectomized rats compared with the
sham-operated rats (Figure 5B). The phospho-JNK/total
JNK ratios were significantly decreased by sitagliptin
treatment. From these results, the antioxidant effect
of catalase decreased the activity of JNK in the
nephrectomized rats after sitagliptin treatment.
To investigate the extent of apoptosis, we examined
kidney sections after detecting DNA fragmentation with
an in situ TUNEL assay. Scattered and bright nuclei
stained by the TUNEL assay were easily detected in the
kidneys of nephrectomized rats, but the number of
nuclei was significantly decreased in the kidneys of thesitagliptin-treated rats (Figure 6A). Next, we examined
changes in the proapoptotic proteins caspase-3, caspase-9,
and Bax by western blot analysis. The cleaved subtypes of
both caspase-3 and caspase-9, and Bax were increased in
the kidneys of nephrectomized rats (Figure 6B). However,
treatment with sitagliptin significantly reduced the
levels of Bax and cleaved subtypes of both caspase-3
and caspase-9 in the nephrectomized rats. These results
indicate that sitagliptin reduces the extent of apoptosis in
the kidneys of nephrectomized rats.
Subtotal nephrectomy was associated with macrophage
infiltration in the tubulointerstitium, as determined by an
increase in ED-1-positive cells (Figure 7). After counting
PI3K






































































Figure 3 Effects of sitagliptin on PI3K and Akt activity.
Representative western blot and group data showing PI3K protein
abundance and Akt phosphorylation in the kidneys of rats from
each group. The intensity of the bands corresponding to PI3K was
corrected by β-actin levels, and phospho-Akt intensity was corrected
by total Akt levels. The results are expressed as the mean ± s.d.
*Significantly different with respect to the sham-operated rats;
#significantly different with respect to the nephrectomized rats;
*#P < 0.05. Sham, sham operation; Nx, nephrectomy; Nx+STG,











































Figure 4 Effects of sitagliptin on FoxO3a phosphorylation.
Representative western blot and group data showing FoxO3a
phosphorylation in the kidneys of rats from each group. The
intensity of the bands corresponding to phospho-FoxO3a was
corrected by total FoxO3a levels to obtain relative measures of
FoxO3a phosphorylation among all samples. The results are
expressed as the mean ± s.d. *Significantly different with respect to
the sham-operated rats; #significantly different with respect to the
nephrectomized rats; *#P < 0.05. Sham, sham operation; Nx,
nephrectomy; Nx+STG, nephrectomy and sitagliptin treatment.
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marked increase in macrophage infiltration after nephrec-
tomy and a significant reduction in response to sitagliptin
treatment. The mean ED-1 score was 94.29 ± 48.51 in
nephrectomized rats and 34.33 ± 14.12 in sitagliptin-
treated nephrectomized rats.
Discussion
This study demonstrated that sitagliptin treatment after
renal mass reduction showed a renoprotective effect. To
the best of our knowledge, this report is the first one to
show the effects of sitagliptin, a DPP IV inhibitor, on
renal damage in the remnant kidney model. Sitagliptin
ameliorated renal dysfunction and attenuated glomerular
and tubulointerstitial injury in this model. Treatmentwith sitagliptin was found to exert anti-oxidative,
anti-apoptotic, and anti-inflammatory effects in this
model, together with the inactivation of the PI3K-Akt
pathway and the resulting activation of FoxO3a.
In this study, sitagliptin, anti-diabetic drug, did not
reduce blood glucose levels in the nephrectomized
rats. Therefore, the renoprotective effect of sitagliptin
is irrelevant to the reduction of glycemia. DPP IV
inhibition does not cause hypoglycemia in a study in
healthy male volunteers [19]. Because the action of GLP-1
on insulin secretion is strictly glucose dependent, the risk
of hypoglycemia associated with DPP IV inhibitors is
low [20].
In the kidney, GLP-1R is strongly expressed in both
the glomeruli and proximal tubules [4,21]. However, it has
been reported that its expression is reduced in diabetic
kidneys [4,7]. In the heart, the GLP-1R mRNA expression
was significantly reduced after subtotal nephrectomy [22].
We first found that GLP-1R expression was markedly
decreased in the kidney after subtotal nephrectomy. Judging
from the complete inhibition of DPP IV activity in
sitagliptin-treated rats, we are sure that sitagliptin signifi-
cantly raised plasma GLP-1 levels. It has been reported that
GLP-1 agonist acts a renoprotective role through increasing
GLP-1R expression in diabetic kidneys [4]. Therefore,
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Sham                 Nx                 Nx+STGB
β-actin 43 kDa
Figure 5 Effects of sitagliptin on oxidative stress. Representative western blot and group data showing catalase expression (A) and JNK
phosphorylation (B) in the kidneys of rats from each group. The intensity of the bands corresponding to catalase was corrected by β-actin levels,
and phospho-JNK intensity was corrected by total JNK levels. The results are expressed as the mean ± s.d. *Significantly different with respect to
the nephrectomized rats; *P < 0.05. Sham, sham operation; Nx, nephrectomy; Nx+STG, nephrectomy and sitagliptin treatment; JNK, c-Jun
N-terminal kinase.
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renal GLP-1R through DPP IV inhibition because the
protein abundance of GLP-1R was significantly increased in
kidney homogenates. The dose of sitagliptin used in this
study was far above the dose of anti-diabetic usage. To
prove the tissue protective effects of DPP IV inhibition, we
determined the dose from previous studies [13,23].Currently, various target genes of FoxOs have been
identified in insulin-responsive tissues [24,25]. There-
fore, the connection between GLP-1 and FoxO has only
been studied in pancreatic beta cells [26]. There are a
few studies that have investigated FoxO signaling in
the kidney [27,28]. Our study is the first to examine
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2.5
Figure 6 Effects of sitagliptin on apoptosis. Apoptotic cells detected in the kidneys stained with TUNEL (A). Representative western blot and
group data showing cleaved caspase-3, cleaved caspase-9, and Bax protein abundance in the kidneys of rats from each group (B). The intensity
of the bands corresponding to cleaved caspase-3, cleaved caspase-9, and Bax was corrected by β-actin levels. The results are expressed as the
mean ± s.d. *Significantly different with respect to the sham-operated rats; #significantly different with respect to the nephrectomized rats;
*#P < 0.05. Sham, sham operation; Nx, nephrectomy; Nx+STG, nephrectomy and sitagliptin treatment. Magnification × 200.
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tus of FoxO3 in this study because it is the most
abundant protein among FoxO subfamily members.
The activation of PI3K, the phosphorylation of Akt,
and the inactivation of FoxO3a were the main pathway
in this disease model. Sitagliptin treatment reversed
this pathway.
Although the precise mechanism remains to be eluci-
dated, CKD has been to known to be associated with
oxidative stress [29,30]. Oxidative stress can occur either
as a result of an increased ROS generation, a depressed
antioxidant system or both. Catalase is a peroxidase
enzyme that is of the major antioxidant defense systems
[31]. However, catalase expression and JNK phos-
phorylation were not changed in this study. Future
studies are needed to address these issues. GLP-1Ractivation using a GLP-1 analog or DPP IV inhibitor
reduced oxidative stress in diabetic nephropathy and
renal IRI [4,5,7,8]. The specific mechanism under-
lying the anti-oxidative effect of GLP-1R activation
remains unclear. In this study, we speculate that the
underlying mechanism might be the up-regulation of
antioxidant catalase by FoxO3a activation through
sitagliptin treatment.
An anti-apoptotic effect mediated by GLP-1R has
been suggested in various tissues, including pancrea-
tic beta cells [32], neurons [33], and cardiomyocytes
[12]. GLP-1R activation also inhibited apoptosis in
diabetic retinopathy [34] and diabetic nephropathy
[4,7]. The underlying anti-apoptotic mechanism of
GLP-1R has been reported in many in vitro studies






























Figure 7 Effects of sitagliptin on the infiltration of macrophages. Immunohistochemical stainings for ED-1 in representative kidneys of
experimental animals. The number of ED-1-positive cells per field was counted in each group. The results are expressed as the mean ± s.d.
*Significantly different with respect to the sham-operated rats; #significantly different with respect to the nephrectomized rats; *#P < 0.05. Sham,
sham operation; Nx, nephrectomy; Nx+STG, nephrectomy and sitagliptin treatment. Magnification × 200.
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anti-apoptotic protein Bcl-2, phosphorylation and
inactivation of Bad, reducing caspase-3 activity and DNA
fragmentation.
Inflammatory cell infiltration induced by subtotal
nephrectomy was attenuated by sitagliptin treatment in
this study. A GLP-1R agonist showed anti-inflammatory
effects in diabetic nephropathy [4,5]. In kidney IRI,
GLP-1R activation using a DPP IV inhibitor amelio-
rated inflammation [8]. The anti-inflammatory effect
of GLP-1R activation was also reported in the animal
model of atherosclerosis [41]. Therefore, we speculate
that GLP-1R activation by sitagliptin in a CKD animal
model showed similar results.
Our study has some limitations. First, we performed
the experiments with only three groups of animals
without a group of animals with sham-operation and
sitagliptin treatment. Due to treatment with a high
dose of sitagliptin, we should have included this
experimental group to observe any adverse effects in
the animals. However, higher doses of sitagliptin than
those used in our experiment have been proven to be
safe in previous studies [12,18]. Moreover, our experi-
ment showed no significant effects on body weight
gain or the changes in blood glucose levels in theanimals. Second, there is insufficient evidence that
the beneficial effect of sitagliptin is through the acti-
vation of GLP-1R. DPP IV acts on a wide range of
substrates. There is a possibility that other target
molecules of DPP IV except GLP-1 may exert the
renoprotective effects because plasma GLP-1 levels
were not measured in this study. Knockout experi-
ments inhibiting GLP-1 or GLP-1R would be required
in the future. Third, there is no direct evidence to
determine the causal relationship between GLP-1R
and FoxO3a signaling. In vitro experiments using
renal cells would also be required to study the direct
effects of the GLP-1R on the signaling proteins (PI3K,
Akt, JNK, and FoxO3a).
Conclusions
In summary, sitagliptin treatment attenuated renal dys-
function and structural damage in a model of renal mass
reduction. A reduction of apoptosis, inflammation and
an increase of antioxidant could be suggested as a
renoprotective mechanism, together with the activation
of FoxO3a signaling. Therefore, DPP IV inhibitors
might provide a promising approach for treating
CKD, but their application in clinical practice remains
to be investigated.
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